VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYMR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYMRKymera Therapeutics, Inc.
$121.13$10.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKYMRBalance Sheet

Kymera Therapeutics, Inc. (KYMR) Balance Sheet

8Y historyFree accessUpdated daily

Leverage is minimal with total debt of roughly $76M to $88M and a debt-to-equity ratio falling from 0.13 to 0.05, as equity growth from external capital raises diluted rather than repaid obligations.

Income StatementBalance SheetCash FlowRatios

KYMR Balance Sheet

Annual statement

KYMR Balance Sheet

Kymera Therapeutics, Inc. (KYMR) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets998.59M871.21M510.27M405.32M419.42M451.27M302.34M92.84M41.79M
Cash & Short-Term Investments971.21M848.28M488.74M374.88M407.17M442.42M296.2M91.96M41.26M
Cash Only373.37M357.01M120.26M109.97M68.39M47.98M31M76.02M41.26M
Short-Term Investments597.84M491.26M368.49M264.92M338.77M394.44M265.2M15.94M0
Accounts Receivable00947K18.76M2.54M135K1.43M0148K
Days Sales Outstanding17.85-7.3487.1419.780.6815.37--
Inventory000000000
Days Inventory Outstanding6.97--------
Other Current Assets27.38M22.94M20.58M11.67M9.71M0000
Total Non-Current Assets768.68M871.6M467.77M170.44M183.72M154.63M184.84M23.86M2.44M
Property, Plant & Equipment78.69M85.53M97.86M101.08M22.24M21.31M20.69M22.08M2.24M
Fixed Asset Turnover1.24x0.46x0.48x0.78x2.11x3.42x1.65x0.13x-
Goodwill000000000
Intangible Assets000000000
Long-Term Investments3.16B776.96M362.16M61.43M152.33M125.19M162.53M0199K
Other Non-Current Assets15.32M9.11M7.74M7.93M9.15M8.14M1.62M1.77M0
Total Assets1.77B1.74B978.03M575.76M603.13M605.9M487.18M116.7M44.23M
Asset Turnover0.06x0.02x0.05x0.14x0.08x0.12x0.07x0.03x-
Asset Growth %265.78%78.2%69.87%-4.54%-0.46%24.37%317.45%163.85%-
Total Current Liabilities89.72M83.21M67.77M85.69M71.34M92.54M110.62M34.57M4.69M
Accounts Payable11.92M4.01M5.99M7.08M4.33M4M4.37M3.28M2.06M
Days Payables Outstanding-45.15------1.45K3.66K
Short-Term Debt013.76M0000000
Deferred Revenue (Current)22.93M22.93M13.58M37.88M35.26M61.74M92.55M23.35M2.32M
Other Current Liabilities905K24.2M223K23.16M303K228K106K01.31M
Current Ratio11.13x10.47x7.53x4.73x5.88x4.88x2.73x2.69x8.92x
Quick Ratio11.13x10.47x7.53x4.73x5.88x4.88x2.73x2.69x8.92x
Cash Conversion Cycle69.98--------
Total Non-Current Liabilities63.02M79.94M74.65M95.1M41.64M53.73M92.67M156.54M73.98M
Long-Term Debt000000000
Capital Lease Obligations263.11M68.5M74.65M78.33M13.39M14.36M14.73M17.82M393K
Deferred Tax Liabilities000000000
Other Non-Current Liabilities0000248K66K100K109.08M73.59M
Total Liabilities152.74M163.15M142.42M180.79M112.98M146.27M203.29M191.11M78.67M
Total Debt76.6M82.25M87.76M84.67M17.34M17.96M17.99M21.19M695K
Net Debt-296.77M-274.76M-32.49M-25.29M-51.06M-30.01M-13.01M-54.82M-40.56M
Debt / Equity0.05x0.05x0.11x0.21x0.04x0.04x0.06x--
Debt / EBITDA-0.19x--------
Net Debt / EBITDA0.75x--------
Interest Coverage-1279.94x-1250.50x-898.03x-748.81x-878.59x-571.67x-395.46x-895.65x-1340.69x
Total Equity1.61B1.58B835.62M394.97M490.15M459.64M283.89M-74.41M-34.44M
Equity Growth %310.84%89.04%111.56%-19.42%6.64%61.91%481.54%-116.07%-
Book Value per Share16.1318.7211.146.779.099.586.37-1.67-0.77
Total Shareholders' Equity1.61B1.58B835.62M394.97M490.15M459.64M283.89M-74.41M-34.44M
Common Stock9K8K7K6K6K5K4K00
Retained Earnings-1.33B-1.07B-754.61M-530.75M-383.79M-228.98M-128.76M-76.46M-35.21M
Treasury Stock000000000
Accumulated OCI-14.73M1.8M-1.49M-552K-4.95M-660K-128K6K0
Minority Interest000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Cash runway tied to financing

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Base Rebuilt Through Capital Raises

Based on KYMR's reported figures, total equity climbed from about $685M in 2024Q2 to roughly $1.6B in 2026Q3, a rise that appears driven by external capital rather than retained operating earnings given the deepening accumulated deficit.

Retained earnings moved from -$621M to -$1.3B over the same ten quarters, so the equity expansion reflects new paid-in capital absorbing a steady stream of losses. This suggests the balance sheet is strengthening in headline terms while the underlying earnings base continues to erode. Investors should monitor whether future equity additions keep pace with the burn rate.

Cash Buffer Swings With Financing Timing

According to reported balance sheet data, KYMR's cash position moved from $67.6M in 2024Q2 to $373.4M in 2026Q3, with a current ratio consistently above 7x, which on its face indicates ample near-term liquidity.

The lumpy quarter-to-quarter cash levels, such as the drop to $124.5M in 2026Q2 followed by a rebound, appear to reflect the timing of financing inflows relative to quarterly cash burn of roughly $60M to $130M in net losses. A current ratio this high is largely a function of the low liability base, not operating strength. The relevant question is how many quarters the current cash balance covers at the latest burn rate, which warrants further investigation.

Minimal Leverage Keeps Balance Sheet Flexible

Based on reported figures, KYMR's total debt has held between $76M and $88M across the period while the debt-to-equity ratio fell from 0.13 to 0.05, indicating leverage has been diluted by equity growth rather than reduced through repayment.

Because debt has been essentially flat in dollar terms, the improvement in D/E reflects the expanding equity denominator rather than deleveraging. The modest debt load does not appear to create near-term refinancing pressure, but it still carries fixed obligations against a business with no recurring product cash flow. Total liabilities of $130M to $163M suggest limited additional claims beyond the stated debt.

Asset Base Is Cash and Intangible-Light

As reported in financial statements, KYMR carries zero goodwill across all ten quarters and net PP&E of roughly $79M to $100M, placing the asset mix firmly in cash and productive capital rather than acquisition-driven intangibles.

The absence of goodwill removes impairment risk that often distorts biotech balance sheets after acquisitions, making reported asset values more directly tied to cash and facilities. The steady decline in net PP&E from $100.4M to $78.7M appears to reflect depreciation outpacing new capital expenditure. Asset quality is therefore relatively clean, though the value of the asset base depends on the success of the research pipeline rather than on any hard operating assets.

Deferred Revenue Masks Limited Recurring Income

Based on KYMR's reported figures, deferred revenue fell from $22.4M in 2024Q2 to zero by 2026Q3, which may indicate that collaboration prepayments have been fully recognized rather than replenished.

A balance sheet showing no deferred revenue in the latest periods means the forward-visibility cushion from upfront partner payments has largely disappeared. Headline liquidity therefore rests almost entirely on equity and debt funding instead of contracted future receipts. This distortion matters because the strong current ratio can overstate financial resilience if no new collaboration prepayments arrive.

KYMR — Frequently Asked Questions

Quick answers to the most common questions about buying KYMR stock.

What are the total assets of Kymera Therapeutics, Inc. (KYMR)?

As of 2025, Kymera Therapeutics, Inc. (KYMR) had total assets of $1.74B including $871.2M in current assets.

How much debt does Kymera Therapeutics, Inc. (KYMR) have?

Kymera Therapeutics, Inc. (KYMR) carries total debt of $82.3M, offset by $848.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Kymera Therapeutics, Inc.?

Kymera Therapeutics, Inc. (KYMR) has total shareholders' equity (book value) of $1.58B ($18.72 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Kymera Therapeutics, Inc.'s current ratio and liquidity?

Kymera Therapeutics, Inc. (KYMR) reported a current ratio of 10.47x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.